Studies have reported that immunosuppressive CD163+ M2 macrophages are prevalent in peritoneal metastatic tissues and ascites from gastric cancer patients, suggesting their potential role in dampening the efficacy of ICI treatments [22, 23]. Here, CD163 is linked to gastric cancer.